Call Us: 888-488-5750

Rebate Audits Are On the Rise—Is Your Program Ready?

As healthcare organizations look to rebate programs to offset tightening margins, audit readiness is becoming a strategic necessity.

Increased scrutiny from manufacturers and evolving requirements around documentation, PHI use, and clinical coding are shifting rebate submissions from “nice-to-have” to regulated deliverables.

Common Audit Pitfalls

  • Incomplete or misaligned NDC/HCPCS mapping
  • Lack of sourcing documentation, especially for physician-administered drugs
  • Submitting PHI when not necessary—or failing to submit minimum required elements
  • Using a one-size-fits-all model across different rebate programs

What an Audit-Ready Program Looks Like

  • Traceable, clean claims with supporting encounter-level data
  • Documentation protocols tailored to manufacturer expectations
  • Policy alignment that ensures only eligible, verified claims are submitted
  • De-identification practices that respect HIPAA minimum necessary standards

How VativoRx Supports Clients

  • We design rebate programs that balance:
  • Compliant claim documentation
  • Automation that scales
  • Minimal burden on provider or health plan teams

If you’re unsure whether your program can stand up to audit scrutiny, we can help you get there.

Contact us to schedule a rebate review or learn how to strengthen your audit trail.

Pharma Tariffs and Specialty Drug Cost Management: What Health Plans and TPAs Should Be Watching

On April 2nd, the White House signed a proclamation imposing new tariffs on patented pharmaceutical products under Section 232 of the Trade Expansion Act of 1962, the same national security trade authority underlying longstanding tariffs on steel and aluminum. The headline rate is 100%. But for health plans and TPAs managing specialty drug costs, that number requires context before it becomes useful for strategic rebate management and financial planning.

Read More »

When Drug Negotiation Reaches Part B

For years, Medicare drug price negotiation was mostly discussed as a Part D story. That changed in January, when CMS selected 15 drugs for the third cycle of negotiation, including the first drugs payable under Medicare Part B. Negotiations take place in 2026, and any negotiated prices from this cycle take effect in 2028.

Read More »